Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton Sells 2,980 Shares of Stock

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 2,980 shares of the stock in a transaction on Monday, March 24th. The stock was sold at an average price of $6.94, for a total value of $20,681.20. Following the sale, the chief executive officer now directly owns 762,419 shares in the company, valued at approximately $5,291,187.86. This trade represents a 0.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 17th, Jerrell Shelton sold 4,620 shares of Cryoport stock. The shares were sold at an average price of $6.29, for a total value of $29,059.80.
• On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The stock was sold at an average price of $4.88, for a total transaction of $20,364.24.

Cryoport Stock Performance

NASDAQ CYRX opened at $6.22 on Thursday. The firm’s fifty day moving average price is $6.73 and its two-hundred day moving average price is $7.34. The stock has a market cap of $310.44 million, a PE ratio of -1.84 and a beta of 1.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. Cryoport, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $20.11.

Cryoport (NASDAQ:CYRX) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The firm had revenue of $59.53 million for the quarter, compared to analyst estimates of $58.71 million. During the same period last year, the business earned ($0.29) EPS. On average, equities analysts expect that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Guggenheim initiated coverage on shares of Cryoport in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Cryoport in a research note on Wednesday, March 5th. Finally, UBS Group upgraded Cryoport from a “neutral” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Monday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in CYRX. Thematics Asset Management boosted its position in Cryoport by 176.2% during the 3rd quarter. Thematics Asset Management now owns 1,705,000 shares of the company’s stock worth $13,828,000 after buying an additional 1,087,800 shares during the period. Fred Alger Management LLC raised its stake in shares of Cryoport by 49.9% during the third quarter. Fred Alger Management LLC now owns 2,698,768 shares of the company’s stock valued at $21,887,000 after acquiring an additional 898,481 shares during the last quarter. Cadian Capital Management LP lifted its holdings in shares of Cryoport by 14.1% during the fourth quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company’s stock worth $38,332,000 after purchasing an additional 609,021 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Cryoport in the third quarter worth $3,405,000. Finally, Millennium Management LLC increased its holdings in Cryoport by 11.0% in the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company’s stock valued at $32,208,000 after purchasing an additional 409,353 shares during the period. Institutional investors and hedge funds own 92.90% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.